Zamtocabtagene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous CD4/CD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, zamtocabtagene autoleucel target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.

**Synonyms:** - Autologous Anti-CD20/CD19-targeting Tandem CAR T Cells MB-CART2019.1 - Autologous pLTG1497-transduced CAR T-cells MB-CART2019.1 - MB CART2019.1 - MB-CART2019.1 - MBCART2019.1 - ZAMTOCABTAGENE AUTOLEUCEL